The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Introduction to current and future protein therapeutics: A protein engineering perspective
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For example, several anti-cancer antibodies provide an overall survival benefit, including bevacizumab [42] and trastuzumab [43] in combination with chemotherapy in metastatic colorectal and breast cancers, respectively.”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034 · cited 1×
“For example, there is a growing appreciation that targets are not isolated gene products but integral components of networks of interconnected signaling pathways [46,47].”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 2×
“, interferon-α, tissue plasminogen activator, and erythropoietin) [2].”
BackgroundTherapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Self-citationTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Cited by
The CamSol method of rational design of protein mutants with enhanced solubility
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.026 · Cited by 494
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
“for dermatology (3), gastroenterology (2), obstetrics/gynecology (2), pediatrics (1), pulmonary/respiratory disease (1), and urology (1) (Figure 2c, right).”
BackgroundFc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308
Challenges in design and characterization of ligand-targeted drug delivery systems
Muro, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.052 · Cited by 307
Irani, V., Guy, A. J., Andrew, D., Beeson, J. G., Ramsland, P. A., & Richards, J. S. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.03.255 · Cited by 288
Site-Specific PEGylation of Therapeutic Proteins
Dozier, J., & Distefano, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025831 · Cited by 287
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.015 · Cited by 267
Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications
Tiede, C., Tang, A. A. S., Deacon, S. E., Mandal, U., Nettleship, J. E., Owen, R. L., George, S. E., Harrison, D. J., Owens, R. J., Tomlinson, D. C., et al. (2014) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzu007 · Cited by 163
Corchero, J. L., Gasser, B., Resina, D., Smith, W., Parrilli, E., Vázquez, F., Abasolo, I., Giuliani, M., Jäntti, J., Ferrer, P., et al. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.09.001 · Cited by 133
Huang, J., Ishino, T., Chen, G., Rolzin, P., Osothprarop, T. F., Retting, K., Li, L., Jin, P., Matin, M. J., Huyghe, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204420 · Cited by 121
“To overcome this shortcoming, several strategies have been used to improve the pharmacokinetics of native proteins and peptides, including Fc fusions, albumin fusions, PEGylation, and fusion to other scaffold proteins (Carter, 2011).”
MethodFree energy perturbation calculations of the thermodynamics of protein side-chain mutations
Steinbrecher, T., Abel, R., Clark, A., & Friesner, R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.002 · Cited by 46
Planinc, A., Dejaegher, B., Vander Heyden, Y., Viaene, J., Van Praet, S., Rappez, F., Van Antwerpen, P., & Delporte, C. (2017) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2016-001022 · Cited by 41
Production of Highly Sialylated Monoclonal Antibodies
Raymond, C., Robotham, A., Kelly, J., Lattova, E., Perreault, H., & Durocher, Y. (2012) · Glycosylation · doi:10.5772/51301 · Cited by 20
“Today, Mabs are leading the biotherapeutics market as 28 have been approved in Europe and the USA, and hundreds are in clinical trials [2-4].”
Background(2022) · doi:10.1002/pro.4557 · Cited by 12
Metadata
- Authors
- Carter, P. J.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 317
- Issue
- 9
- Pages
- 1261-1269
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2025629542
- Cited by
- 467
- References
- 63
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.